Kiniksa Pharmaceuticals International (KNSA) Assets Average (2018 - 2026)

Kiniksa Pharmaceuticals International has reported Assets Average for 9 years, with the latest figure at $794.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 34.67% year-over-year to $794.5 million; the trailing twelve-month figure through Mar 2026 stood at $794.5 million (up 34.67% YoY), and the FY2025 full-year result was $672.1 million, up 21.44% from the prior year.
• Assets Average for Q1 2026 stood at $794.5 million, up from $738.0 million in the prior quarter.
• The five-year high for Assets Average was $794.5 million in Q1 2026, with the low at $220.8 million in Q2 2022.
• Historically, Assets Average has averaged $515.4 million across 5 years, with a median of $523.0 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average retreated 29.8% — and 2023, when it jumped 109.99%.
• Kiniksa Pharmaceuticals International's Assets Average stood at $459.8 million in 2022, then gained by 9.76% to $504.7 million in 2023, then grew by 12.53% to $567.9 million in 2024, then advanced by 29.94% to $738.0 million in 2025, then increased by 7.65% to $794.5 million in 2026.
• The last three Assets Average figures came in at $794.5 million (Q1 2026), $738.0 million (Q4 2025), and $686.7 million (Q3 2025), per Business Quant data.